ClinicalTrials.gg
Not yet recruitingNCT07705100UBCTUpdated Jul 27, 2026

Clinical Feasibility Study of Upright, Low-dose, High-resolution, 3D Breast CT (UBCT).

An interventional study of Low dose, upright, dedicated breast CT in Breast Cancer Detection, sponsored by University of Arizona. Not yet recruiting. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by University of Arizona · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by University of Arizona — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · University of Arizona.

Planned enrollment
10th of 28
50 · median 28
Started
2026
the only one that year
No phase
10 of 32
2 open now
Registered
32nd of 32
by date

Among the 32 studies in Breast Neoplasms by University of Arizona, this one is the 10th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 32nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 32 studies in Breast Neoplasms by University of Arizona are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by University of Arizona, or all of them as a file.
02

Study summary

The investigators are doing this study to find out if a new kind of breast imaging (called upright dedicated breast CT or UBCT) can help doctors to see the small structures in breast tissue more clearly in 3-D and without overlap.

The breast imaging device that will be used in this study (UBCT) is not FDA-approved, so this is a research study. The machine has been designed to remove mammography-like breast compression and use radiation dose comparable to mammography. The breast CT device will take multiple x-ray pictures of the subjects breast in approximately 20 seconds and create a 3-D image of the breast. It does not compress or squish the breast like a mammogram.

03

Conditions studied

  • Breast Cancer Detection

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the screening cohort, the inclusion criteria are, women:

  • (1) who were 40 years of age or older (typical screening age range), and,
  • (2) who were asymptomatic, and,
  • (3) who underwent or scheduled to undergo a standard-of-care 2-view bilateral digital breast tomosynthesis screening exam.

For the diagnostic cohort, the inclusion criteria are, women:

  • (1) who were 40 years of age or older, and,
  • (2) who underwent a standard-of-care 2-view bilateral digital breast tomosynthesis exam, and,
  • (3) who were assigned BI-RADS category 4 or 5 after diagnostic work-up and are scheduled for .

Exclusion criteria

Exclusion Criteria:

  • Males
  • Women less than 40 years old
  • pregnant or lactating women
  • women with physical limitations (e.g., kyphosis) that may prohibit UBCT exam
  • women who have received radiation treatments to the thorax
  • women who have participated in a prior breast clinical trial that gave additional radiation dose
  • women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as tuberculosis, and severe scoliosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Screening cohort

    Women who undergo breast cancer screening using mammography and/or digital breast tomosynthesis.

    Device: Low dose, upright, dedicated breast CT

  • Experimental
    Diagnostic cohort

    Women who have suspicious finding(s) that require biopsy.

    Device: Low dose, upright, dedicated breast CT

Interventions

  • DeviceLow dose, upright, dedicated breast CT

    This study investigates the feasibility of an upright, dedicated breast CT (UBCT) for breast cancer detection.

    Also known as: UBCT

06

What researchers measure

Primary outcomes

  1. Feasibility of UBCT

    The proportion of participants who successfully complete the imaging exam using upright, dedicated breast CT (UBCT).

    Time frame: From enrollment to end of study in approximately 6 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — IPD information may be shared with individual academic investigators in accordance with the University of Arizona's data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 4 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07705100
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 27, 2026

Study contacts

Michele N Galvan, R.T.
Contact
mngalvan@arizona.edu
520-626-2279
Srinivasan Vedantham, PhD
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion